Marksans Pharma announces UK MHRA approval for Bells Healthcare All in One Oral Solution

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) has announced that UK MHRA has granted Market Authorisation to the Company's wholly owned subsidiary Bell Sons & Co. (Druggists) Limited for Bells Healthcare All in One Oral Solution.

Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg.

Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs.

This is the first generic approval by UK MHRA for the product.

Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) Limited in UK.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 49.65 as compared to the previous close of Rs. 51.05. The total number of shares traded during the day was 302865 in over 2039 trades.

The stock hit an intraday high of Rs. 51.55 and intraday low of 48.90. The net turnover during the day was Rs. 15083809.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 UKMHRA MarketAuthorisation